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Abstract Caveolin-3, a muscle-specific caveolin-related protein,
is the principal structural protein of caveolae membrane domains
in striated muscle cell types (cardiac and skeletal). Recently, we
identified an autosomal dominant form of limb girdle muscular
dystrophy in humans that is due to mutations within exon 2 of the
caveolin-3 gene (3p25). However, the detailed location of the
human caveolin-3 gene and its position with regard to neighbor-
ing genes remains unknown. Here, we have isolated three
independent BAC clones containing the human caveolin-3 gene.
Using a PCR-based approach, we determined that these clones
contain both exons 1 and 2 of the human caveolin-3 gene. In
addition, we performed microsatellite marker analysis of these
BAC clones, using a panel of 13 markers that are known to map
within the 3p25 region. Our results indicate that these BAC
clones contain the following three markers: D3S18, SHGC-1079
(also known as D3S4163) and D3S4539. Interestingly, D3S18 is
a marker for two known human diseases, von Hippel-Lindau
disease and 3p-syndrome. As D3S4163 and D3S4539 are known
to map in the vicinity of the 3P end of the human oxytocin
receptor gene, we determined if these caveolin-3 positive BACs
also contain the oxytocin receptor gene. We show that (i) these
BACs contain all four exons of the oxytocin receptor gene and
(ii) that the genes encoding caveolin-3 and the oxytocin receptor
are located V7^10 kb apart and in the opposite orientation. As
3p-syndrome is characterized by cardiac septal defects and
caveolin-3 is expressed primarily in the heart and skeletal
muscle, caveolin-3 is a candidate gene that may be deleted in 3p-
syndrome.
z 1999 Federation of European Biochemical Societies.
1. Introduction
Caveolae are 50^100 nm vesicular invaginations of the plas-
ma membrane [1]. It has been proposed that caveolae partic-
ipate in vesicular tra⁄cking events and signal transduction
processes [2^5]. Caveolin, a 21^24 kDa integral membrane
protein, is a principal component of caveolae membranes in
vivo [6^10]. Caveolin is only the ¢rst member of a new gene
family. As a consequence, caveolin has been re-termed caveo-
lin-1 [11].
The mammalian caveolin gene family now consists of cav-
eolins-1, -2 and -3 [4,5,11^13]. Caveolins-1 and -2 are co-ex-
pressed and form a hetero-oligomeric complex [14] in many
cell types, with particularly high levels in adipocytes, whereas
expression of caveolin-3 is muscle-speci¢c and found in both
cardiac and skeletal muscle [15]. The expression of caveolin-3
is induced during the di¡erentiation of skeletal myoblasts and
caveolin-3 is localized to the muscle cell plasma membrane
(sarcolemma) where it forms a complex with dystrophin and
its associated glycoproteins [15]. However, under certain con-
ditions, caveolin-3 can be physically separated from the dys-
trophin complex [16]. This indicates that although caveolin-3
is dystrophin-associated, it is not absolutely required for the
biogenesis of the dystrophin complex [16].
Caveolin-3 is most closely related to caveolin-1 based on
protein sequence homology. Caveolin-1 and caveolin-3 are
V65% identical and V85% similar (see Tang et al. for an
alignment: [13]). However, caveolin-3 mRNA is expressed
predominantly in muscle tissue types (skeletal muscle, dia-
phragm and heart) [13]. Identi¢cation of a muscle-speci¢c
member of the caveolin gene family has implications for
understanding the role of caveolins in di¡erent muscle cell
types (smooth, cardiac and skeletal), as previous morpholog-
ical studies have demonstrated that caveolae are abundant in
these cells. A number of studies have highlighted the impor-
tance of caveolae and caveolins in the pathogenesis of Duch-
enne’s muscular dystrophy. More speci¢cally, dystrophin has
been localized to plasma membrane caveolae in smooth
muscle cells using immuno-EM techniques [17] and skeletal
muscle caveolae undergo characteristic changes in their size
and distribution in patients with Duchenne’s muscular dys-
trophy, but not in other forms of neuronal-based muscular
dystrophies examined [18]. This indicates that muscle cell cav-
eolae may play an important role in muscle membrane biol-
ogy.
In collaboration with Minetti and colleagues, we have re-
cently identi¢ed an autosomal dominant form of limb girdle
muscular dystrophy (LGMD-1C) in two Italian families that
is due to a de¢ciency in caveolin-3 expression [19]. Analysis of
their genomic DNA reveals two distinct mutations in the cav-
eolin-3 gene at 3p25, (i) a 9 bp micro-deletion that removes
the sequence TFT from the caveolin-sca¡olding domain and
(ii) a mis-sense mutation that changes a proline to a leucine
(PCL) in the transmembrane domain [19]. Both mutations
lead to a loss of V90% of caveolin-3 protein expression.
These results indicate that dramatic reductions in caveolin-3
can produce a disease phenotype in humans. However, the
detailed location of the human caveolin-3 gene and its posi-
tion with regard to neighboring genes remains unknown.
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Knowledge of the detailed localization of the caveolin-3 gene
might implicate caveolin-3 in the pathogenesis of other human
diseases. Here, we have shown that the human caveolin-3 gene
is located in close proximity to three known microsatellite
markers (D3S18, SHGC-1079 (also known as D3S4163) and
D3S4539) and the oxytocin receptor gene. Interestingly,
D3S18 is a marker for two known human diseases, von Hip-
pel-Lindau disease and 3p-syndrome.
2. Materials and methods
2.1. Isolation of human genomic BAC clones
A probe corresponding to the full-length cDNA of human caveolin-
3 was used to screen a human genomic BAC library (Release I, Ge-
nome Systems), as we described previously for human caveolins-1 and
-2 [20,21]. The presence of the exons of the human caveolin-3 gene
within a given BAC clone was veri¢ed by PCR analysis and DNA
sequencing.
2.2. Microsatellite marker analysis
Isolated human genomic BAC clones containing the human caveo-
lin-3 gene were subjected to microsatellite marker analysis by PCR
with the following 13 Ge¤ne¤thon markers: D3S18, D3S1304, D3S1597,
D3S3591, D3S601, D3S3601, D3S3691, D3S3728, D3S587, D3S4539,
D3S726, D3S732 and SHGC-1079 (D3S4163). Ge¤ne¤thon primer pairs
were obtained from Research Genetics.
2.3. Analysis of the oxytocin receptor gene
The presence of the exons of the human oxytocin receptor gene
within a given caveolin-3 positive BAC clone was determined by
PCR analysis. Primers were designed based on the known sequence
of the intron-exon boundaries of the human oxytocin receptor gene
[22] and are listed in Table 3.
3. Results
3.1. Isolation of BAC clones containing the human caveolin-3
gene
The human cDNA encoding caveolin-3 was used to screen a
human genomic BAC library to obtain corresponding clones
containing the human caveolin-3 gene. Through this screening
approach, a total of three independent positive clones were
isolated. All three clones contain both exons 1 and 2 of the
human caveolin-3 gene (Fig. 1 and Table 1).
3.2. Microsatellite marker analysis of caveolin-3 positive BAC
clones
To more precisely determine the location of the human
caveolin-3 gene, we next performed microsatellite marker
analysis on the corresponding human genomic BAC clones.
As 3p25 corresponds to a region that is frequently deleted in
von Hippel-Lindau disease and 3p-syndrome, numerous mi-
crosatellite markers have been used for LOH analysis of this
region. Through literature searches, we identi¢ed the 13 most
commonly used markers as follows: D3S18, D3S1304,
D3S1597, D3S3591, D3S601, D3S3601, D3S3691, D3S3728,
D3S587, D3S4539, D3S726, D3S732 and SHGC-1079
(D3S4163). These markers, corresponding primer sequences
and the expected size of their PCR products are as indicated
in Table 2.
Fig. 2 shows that three microsatellite markers were detected
(D3S18, SHGC-1079 (also known as D3S4163) and D3S4539)
and are present in all three caveolin-3 genomic clones. A
search of the GenBank data base indicated that the markers
SHGC-1079 (also known as D3S4163) and D3S4539 are lo-
cated at the 3P end of the human oxytocin receptor gene at
3p25 [23]. These results indicate that the human caveolin-3
gene must be located near the human oxytocin receptor gene.
3.3. The human caveolin-3 gene is located in close proximity to
the human oxytocin receptor gene
Given our results from the microsatellite marker analysis,
we next determined if our caveolin-3 positive BAC clones
contain the human oxytocin receptor gene.
Primers were designed to PCR amplify the four exons of the
human oxytocin receptor gene. These primers and the ex-
pected size of their PCR products are as indicated in Table
3. All four exons of the human oxytocin receptor gene were
detected (Fig. 3) and are present in all three caveolin-3 ge-
nomic clones (data not shown).
As the average insert size of these human genomic BAC
clones isV100 kb, these data indicate that the genes encoding
Fig. 1. Caveolin-3 positive BAC clones contain exons 1 and 2 of
the human caveolin-3 gene. The presence of the exons of caveolin-3
within a given BAC clone was determined by PCR using the primer
pairs listed in Table 1. Note that all three BAC clones contain both
exons 1 and 2 of the human caveolin-3 gene.
Fig. 2. The human caveolin-3 gene is located in close proximity to
three microsatellite markers: D3S18, SHGC-1079 (also known as
D3S4163) and D3S4539. Primers corresponding to 13 Ge¤ne¤thon mi-
crosatellite markers from the 3p25 region were used to perform
PCR analysis employing the human genomic caveolin-3 BAC clones
as the template. Note that three PCR products of the expected size
(see Table 2) were observed and correspond to the markers D3S18
SHGC-1079 (also known as D3S4163) and D3S4539.
Table 1
Primer pairs used to amplify the exons of the human caveolin-3 gene and the expected size of their PCR products
hCav-3 gene Forward primer (5C3) Reverse primer (5C3) Expected size (bp)
hCav-3 Ex 1 ATGGCAGAAGAGCACACAGAT CTTGACTATGTCCTCGTTAAT 114
hCav-3 Ex 2 GTGGATTTTGAAGACGTGATC TTAGACCTCCTTCCGCAGCAC 342
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human caveolin-3 and the oxytocin receptor must be located
at a maximum distance of V100 kb from each other.
In this regard, it is interesting to note the historical context
in which the ¢rst cDNA isolated for caveolin-3 was cloned
[13]. Searches of the GenBank database with the human cav-
eolin-1 protein sequence revealed a striking homology after
translation with a DNA sequence entry presumed to encode
the 3P end of the rat oxytocin receptor gene (accession number
U15280) [13]. This homologous DNA sequence was PCR-am-
pli¢ed from rat genomic DNA and used as a probe to screen a
rat heart cDNA library. The isolated clones were expressed in
a muscle-speci¢c manner and were designated caveolin-3, be-
cause of their close homology with caveolins-1 and -2 [13]. We
now know that this originally identi¢ed rat genomic sequence
represents exon 2 of the rat caveolin-3 gene. Re-analysis of
this rat genomic DNA sequence data indicates that the second
exon of the rat caveolin-3 gene is located V3.5 kb down-
stream of the last exon of the rat oxytocin receptor gene
and in the opposite orientation. This would suggest that a
similar organization may exist for the corresponding locus
in humans.
To test this hypothesis directly, we designed primer pairs
based on the 3P ends of the last exons of the human caveolin-3
and oxytocin receptor genes. PCR-based analysis of these
caveolin-3 positive genomic clones using these primers re-
vealed a single band of V7^10 kb. In addition, this band
was not observed when the same reaction was carried out
with the empty BAC vector, clearly indicating that this am-
pli¢cation product was speci¢c (Fig. 4). These results suggest
that the distance between the ends of the human caveolin-3
and oxytocin receptor genes is V7^10 kb and that they are
indeed present in the opposite orientation (Fig. 5), as pre-
dicted based on analysis of the rat genomic sequence data.
4. Discussion
Here, we have determined that the human caveolin-3 gene is
located within close proximity to three microsatellite markers
located at 3p25, D3S18, SHGC-1079 (also known as
D3S4163) and D3S4539. Interestingly, D3S18 is a marker
for two known human diseases, von Hippel-Lindau disease
Fig. 4. The distance between the caveolin-3 gene and the oxytocin
receptor gene is V7^10 kb. Primer pairs based on the 3P ends of
the last encoding exons of the human caveolin-3 and oxytocin re-
ceptor genes were used to perform PCR analysis of the caveolin-3
positive genomic clones. Note that a single band of V7^10 kb was
observed in all three genomic clones (lanes 1^3). In addition, this
band was not observed when the same reaction was carried out
with the empty BAC vector (lane 4), clearly indicating that this am-
pli¢cation product was speci¢c.
Fig. 3. Caveolin-3 positive BAC clones contain all four exons of the
human oxytocin receptor gene. Primers corresponding to the four
exons of the human oxytocin receptor gene were used to perform
PCR analysis employing the human genomic caveolin-3 BAC clones
as the template. These primers and the expected size of their PCR
products are as indicated in Table 3. Note that all four exons of
the human oxytocin receptor gene were detected and are present in
all three caveolin-3 genomic clones (data not shown).
Table 2
Commonly used 3p25 microsatellite markers, primer sequences and the expected size of their PCR products
Marker Forward primer (5C3) Reverse primer (5C3) Expected size (bp)
D3S18 CACAAGTGATGCCTTGTAGCTG CAGTAGTGTCCTGTATTTAGTG 200
D3S1304 TTCGCTCTTTGATAGGC ATTTCATTTGTAATTTACTAGCAG 253^269
D3S1597 AGTACAAATACACACAAATGTCTC GCAAATCGTTCATTGCT 162^178
D3S3591 CCAACTATGTTTTGGGTCTG TGTGCCCAGTTAGATGATG 148^152
D3S601 GTTGGCTATGGGTAGAATTGG CAGGGTAGCCTTGATCTAAGT 190
D3S3601 CAGTTACCTTGATAGACTGGTAGT GAGATTTAGTTGACTCACCCAC 239^247
D3S3691 TCTCAGCAATAGCAAACATCAGG TTGAAACCAGGGTGACAAATACATC 250^254
D3S3728 CTGAGGTGGGAGGTTCACTT TTGCCACAAAATGTGCG 222^224
D3S587 TTCCCCTGCACAAGCTG AAGCCTCACAATCATGGTGG 125^143
D3S4539 GCGCAGTGGACCTATTAGAA GTATCTTGAAACCTTGCGGA 236
D3S726 ACTTATTACCTAGCTCCCCt ACAGATGGTTCCAAGCCAGA 200
D3S732 GGTCTGGGTTATACCATGCCT ACTCAATGTCTTTCCTTCCTC 250
SHGC-1079 (D3S4163) GGCGTATGTTTGTGTATAAGGTACC ACCCAAGTCCAGAACACTG 319
Table 3
Primer pairs used to amplify the exons of the oxytocin receptor (OTR) gene
OTR gene Forward primer (5C3) Reverse primer (5C3) Expected size (bp)
hOTR Ex 1 TGTTAAGGCTCTGGGACC CTGCACCGAGTCCGCAGG 383
hOTR Ex 2 TGGAAGCCGCTGAACATC CTCCTCTGAGCCACTGCA 96
hOTR Ex 3 GGTGGACTCAGCAGATCC CTTCCTTGGGCGCGTTGG 1 060
hOTR Ex 4 CCTCGGCCTTCATCATCG CGCCGTGGATGGCTGGGA 240
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and 3p-syndrome. As D3S4163 and D3S4539 are known to
map in the vicinity of the 3P end of the human oxytocin
receptor gene, we also determined if these caveolin-3 positive
BACs contain the oxytocin receptor gene. In this regard, we
¢nd that the genes encoding caveolin-3 and the oxytocin re-
ceptor are located V7^10 kb apart and in the opposite ori-
entation.
3p-syndrome, a hemizygous deletion of 3p25-pter, is char-
acterized by growth retardation, speci¢c cranio-facial features
(microcephaly, ptosis, micrognathia), mental retardation and
cardiac septal defects [24]. In addition, trisomy 3p is associ-
ated with psychomotor and mental retardation, short neck
and congenital heart defects, such as atrial septal defects
and mitral valve clefts [25]. These results suggest that a gene
that is both expressed in the heart and the brain may be
involved in the pathogenesis of these congenital defects. In-
terestingly, caveolin-3 is expressed primarily in skeletal muscle
¢bers, cardiac myocytes and brain astrocytes [13,15,26]. In
addition, we show here that the human caveolin-3 gene is
localized near the D3S18 locus and the D3S18 marker is spe-
ci¢cally deleted in 3p-syndrome. Taken together, these results
suggest that caveolin-3 is a candidate gene that may be deleted
in 3p-syndrome.
A form of dilated cardiomyopathy in humans has also been
mapped to the 3p25 region using linkage analysis [27]. The
closest known marker for this disease is D3S1304 [27] and this
marker was not present in our caveolin-3 positive BAC clones
(Fig. 2). However, since the genetic analysis of dilated cardi-
omyopathy is still in the early stages, our results do not rule
out a role for caveolin-3 in the pathogenesis of dilated cardi-
omyopathy.
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Fig. 5. Overall organization of the caveolin-3/oxytocin receptor lo-
cus. The organization of the human caveolin-3 gene and the human
oxytocin receptor gene was as described previously [19,22,28,29].
Our current ¢ndings demonstrate that the distance between the ends
of the human caveolin-3 and oxytocin receptor genes is V7^10 kb
and that they are indeed present in the opposite orientation. See
text for details.
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